DK0939632T3 - Non-peptidyl vasopressin V1a antagonister - Google Patents

Non-peptidyl vasopressin V1a antagonister

Info

Publication number
DK0939632T3
DK0939632T3 DK97907895T DK97907895T DK0939632T3 DK 0939632 T3 DK0939632 T3 DK 0939632T3 DK 97907895 T DK97907895 T DK 97907895T DK 97907895 T DK97907895 T DK 97907895T DK 0939632 T3 DK0939632 T3 DK 0939632T3
Authority
DK
Denmark
Prior art keywords
antagonists
vasopressin
peptidyl
peptidyl vasopressin
azetidin
Prior art date
Application number
DK97907895T
Other languages
Danish (da)
English (en)
Inventor
Robert F Bruns Jr
Gary A Koppel
Robin D G Cooper
Bruce A Dressman
David C Hunden
Stephen W Kaldor
John R Rizzo
Jeffrey James Skelton
Mitchell I Steinberg
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605044.8A external-priority patent/GB9605044D0/en
Priority claimed from GBGB9605046.3A external-priority patent/GB9605046D0/en
Priority claimed from GBGB9605045.5A external-priority patent/GB9605045D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0939632T3 publication Critical patent/DK0939632T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
DK97907895T 1996-02-23 1997-02-20 Non-peptidyl vasopressin V1a antagonister DK0939632T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1218896P 1996-02-23 1996-02-23
US1214996P 1996-02-23 1996-02-23
US1221596P 1996-02-23 1996-02-23
GBGB9605044.8A GB9605044D0 (en) 1996-03-09 1996-03-09 Method and non-peptidyl agents for modulation of the vasopressin v1a receptor
GBGB9605046.3A GB9605046D0 (en) 1996-03-09 1996-03-09 Method for antagonism of the tachykinin receptor with non-peptide agents
GBGB9605045.5A GB9605045D0 (en) 1996-03-09 1996-03-09 Method and non-peptidyl agents for modulation of the oxytocin receptor

Publications (1)

Publication Number Publication Date
DK0939632T3 true DK0939632T3 (da) 2006-01-30

Family

ID=27547258

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97907895T DK0939632T3 (da) 1996-02-23 1997-02-20 Non-peptidyl vasopressin V1a antagonister

Country Status (10)

Country Link
US (3) US6204260B1 (enExample)
EP (1) EP0939632B1 (enExample)
JP (1) JP4212112B2 (enExample)
AT (1) ATE305781T1 (enExample)
AU (1) AU1977997A (enExample)
CA (1) CA2246753C (enExample)
DE (1) DE69734321T2 (enExample)
DK (1) DK0939632T3 (enExample)
ES (1) ES2248840T3 (enExample)
WO (1) WO1997030707A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5049437B2 (ja) * 1999-08-16 2012-10-17 リヴァアックス ファーマスーティカルズ,エルエルシー 神経治療のための合成物と方法
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
HUP0204278A2 (hu) 1999-11-04 2003-04-28 Ortho-Mcneil Pharmaceutical, Inc. Nem peptid szubsztituált benzotiazepinszármazékok, mint vazopresszin antagonisták, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
CA2446931A1 (en) 2001-06-15 2002-12-27 Vicuron Pharmaceuticals Inc. Pyrrolidine bicyclic compounds
WO2003031407A2 (en) * 2001-10-12 2003-04-17 Serenix Pharmaceuticals, Llc β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
AU2002359761A1 (en) * 2001-12-18 2003-06-30 Invenux, Inc. Antibiotic compounds
JP4560483B2 (ja) * 2002-10-03 2010-10-13 ターゲジェン インコーポレーティッド 血管静態化物質およびそれらの使用法
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US20060281728A1 (en) * 2003-10-03 2006-12-14 Guillon Christophe D 3-Substituted beta-lactamyl vasopressin v1a antagonists
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
EP1799656A4 (en) 2004-08-25 2009-09-02 Targegen Inc HETEROCYCLIC COMPOUNDS AND METHODS OF USE
AU2013206201B2 (en) * 2005-03-22 2016-06-16 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
WO2006102308A2 (en) * 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1b antagonists
BRPI0606172A2 (pt) * 2005-06-08 2009-06-02 Targegen Inc métodos e composições para o tratamento de distúrbios oculares
PL1910346T3 (pl) * 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
KR101467723B1 (ko) 2005-11-01 2014-12-03 탈자진 인코포레이티드 키나제의 비-아릴 메타-피리미딘 억제제
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US7691858B2 (en) * 2006-04-25 2010-04-06 Targegen, Inc. Kinase inhibitors and methods of use thereof
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
BRPI1013901A2 (pt) * 2009-04-29 2019-09-24 Rexahn Pharmaceuticals Inc formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos
WO2012003436A1 (en) 2010-07-01 2012-01-05 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN116139282A (zh) 2014-03-28 2023-05-23 阿泽范药品公司 用于治疗神经退行性疾病的组合物和方法
JP2020534274A (ja) 2017-09-15 2020-11-26 アゼヴァン ファーマシューティカルズ,インコーポレイテッド 脳損傷を治療するための組成物及び方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US4665171A (en) 1985-07-17 1987-05-12 Harvard University Process and intermediates for β-lactam antibiotics
US4673737A (en) 1985-08-02 1987-06-16 Harvard University 7-acylamino-(or 7-amino)-3-trifluoromethylsulfonyloxy-1-carba(1-dethia)-3-cephem-4-carboxylic acids and esters thereof
DK429986A (da) 1985-09-09 1987-03-10 Otsuka Pharma Co Ltd 2-oxa-isocephemforbindelser
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
DK123488A (da) 1987-03-09 1988-09-10 Otsuka Pharma Co Ltd 2-oxa-isocephemforbindelser, praeparater indeholdende dem, og fremgangsmaader til fremstilling af dem
US5373089A (en) 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
US5068232A (en) * 1990-04-10 1991-11-26 American Cyanamid Company Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them
US5521307A (en) 1992-02-18 1996-05-28 Eli Lilly And Company Methods and compounds for the preparation of carbacephems
CA2147129A1 (en) * 1992-10-27 1994-05-11 James B. Doherty New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU4368896A (en) * 1994-11-23 1996-06-17 Affymax Technologies N.V. Methods for synthesizing diverse collections of beta-lactam compounds
JPH11503728A (ja) * 1995-03-31 1999-03-30 シンファー ラボラトリーズ,インコーポレーティッド システイン・プロテイナーゼ阻害剤として有用な新規な4−置換−3−ペプチジル−アゼチジン−2−オン誘導体
AU5487496A (en) * 1995-05-03 1996-11-21 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs

Also Published As

Publication number Publication date
US20020049187A1 (en) 2002-04-25
WO1997030707A1 (en) 1997-08-28
ES2248840T3 (es) 2006-03-16
AU1977997A (en) 1997-09-10
EP0939632B1 (en) 2005-10-05
DE69734321T2 (de) 2006-08-10
CA2246753A1 (en) 1997-08-28
CA2246753C (en) 2005-05-10
JP4212112B2 (ja) 2009-01-21
US6521611B2 (en) 2003-02-18
EP0939632A1 (en) 1999-09-08
JP2000504731A (ja) 2000-04-18
EP0939632A4 (en) 2002-09-25
DE69734321D1 (de) 2006-02-16
US6204260B1 (en) 2001-03-20
US6610680B1 (en) 2003-08-26
ATE305781T1 (de) 2005-10-15

Similar Documents

Publication Publication Date Title
DK0939632T3 (da) Non-peptidyl vasopressin V1a antagonister
PT776324E (pt) Antagonista da endotelina
ATE263151T1 (de) Indolderivate verwendbar als endothelinrezeptorantagonisten
AU3998693A (en) Angiotensin ii antagonists
TR200000812T2 (tr) 2-metil-tieno- benzodiazepin formülasyonu.
AU2464601A (en) Tricyclic protein kinase inhibitors
DE69917663D1 (de) 2-methyl-thieno-benzodiazepin-formulierung
DE69703242D1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
NO20001548D0 (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat
DE69717449D1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
DE69617010D1 (de) Isazole derivate als fibrinogen-rezeptor-antagonisten
DE69526738D1 (de) Endothelin-rezeptor-antagonisten
WO2001012838A3 (en) Compounds which modulate the activity of an lpa receptor
EA199800204A1 (ru) Антагонисты 5-нтрецепторов для лечения дискинезии
ATE342055T1 (de) Verwendung von steroidalen estrogenrezeptorantagonisten zur männlichen fertilitätskontrolle
ECSP972052A (es) Quinoxalinadionas
HK1008990A (en) 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists
FI941117A0 (fi) Bentsyyli-imidatsopyridiinijohdannaiset angiotensiini II reseptoriantagonisteina
HK1025569A (en) Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
BR0002142A (pt) Inibidores de quinase myti